Drug Profile
Rezivertinib - Beta Pharma
Alternative Names: BPI-7711; Rezetinib mesylateLatest Information Update: 04 Nov 2022
Price :
$50
*
At a glance
- Originator Beta Pharma
- Class Amides; Amines; Antineoplastics; Indoles; Phenyl ethers; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Non-small cell lung cancer
Most Recent Events
- 09 Sep 2022 Effiicacy and adverse events data from a phase I/II trial in Non-small cell lung cancer presented at 47th European Society for Medical Oncology Congress (ESMO-2022)
- 03 Jun 2022 Interim efficacy and adverse events data from a phase IIb trial in non-small cell lung cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 27 Apr 2022 Beta Pharma expects NDA approval for Non-small cell lung cancer in the second or third quarter of 2022 (Beta Pharma pipeline, April 2022)